Lucid Diagnostics Inc.
NASDAQ:LUCDMedical - Devices
+$0.04 today
- Market cap
- $79.38M
- Beta
- 1.08
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.44
Volume 2.70M
Average 0.84M
LUCD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Lucid Diagnostics Inc.NASDAQ: LUCD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $13.91M (cash outflow) fell 48.3% year over year, behind the +43056.2% change in trailing-twelve-month net income. Sequentially, it fell 99.9% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.
Context
- Net income amounted to 1232.7% of revenue in FY2025, up 185.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$28.82M (-50.3%) for the fiscal year ending Dec 2026, a slowdown from the +27.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.91M-99.9% QoQ
- Last fiscal yearDec 2025
- -$58.01M+27.4% YoY
- LTMMar 2026
- -$26.68B+43056.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -48.3% | +143.8% | +192.1 pp |
| 1 year | +27.4% | -50.3% | -77.7 pp |
| 3-year CAGR | +1.1% | -34.9% | -36.0 pp |
| 5-year CAGR | -34.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (58.01M) USD
- Year-over-year change
- -27.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (58.01M) | -27.4% |
| FY2024 | 2024-12-31 | (45.53M) | +13.6% |
| FY2023 | 2023-12-31 | (52.67M) | +6.2% |
| FY2022 | 2022-12-31 | (56.17M) | -100.1% |
| FY2021 | 2021-12-31 | (28.08M) | — |
Net Income vs competitors
How LUCD compares with its peers on the latest reported figures
- LUCD's LTM Mar 2026 net income of $26.68B is the largest of the 10 companies compared; the peer median is $70.49M.
- Its year-over-year change of +43056.2% is the highest of 10, against a peer median of +11.8%.
- Net income amounts to 519699.0% of revenue for LUCD, versus a peer median of 468.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.68B | +43056.2% | +1.1% | 519699.0% | |
| LTM Mar 2026 | $380.63M | +410.8% | +148.5% | 1124.1% | |
| LTM Mar 2026 | $358.5M | +5514.8% | +287.7% | 90325.9% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $88.03M | +7.6% | +45.5% | 4756.0% |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $50.14M | +11.8% | -8.1% | 145.8% | |
| LTM Mar 2026 | $46.04M | +260.1% | -21.4% | 43.0% | |
| LTM Mar 2026 | $45.34M | -20.5% | +22.1% | 62.7% | |
| LTM Mar 2026 | $9.05M | -55.1% | -21.9% | 16.2% | |
| Peer median (excluding LUCD) | $70.49M | +11.8% | +7.3% | 468.7% | |
Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.08M) | (56.17M) | (52.67M) | (45.53M) | (58.01M) |
| Depreciation & Amortization | 4K | 1.94M | 2.5M | 1.17M | 872K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.6M | 14.99M | 6.82M | 4.53M | 4.49M |
| Change in Working Capital | 807K | 8.91M | 5.68M | (4.43M) | (2.81M) |
| Accounts Receivables | (200K) | 183K | (28K) | 0 | (601K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (665K) | (445K) | 89K | 96K | (270K) |
| Other Working Capital | 1.67M | 9.17M | 5.61M | (4.53M) | (1.94M) |
| Other Non-Cash Items | 9.6M | 653K | 4.85M | 119K | 8.97M |
| Operating Cash Flow | (17.67M) | (29.69M) | (32.82M) | (44.14M) | (46.49M) |
| Capital Expenditures | (862K) | (908K) | (221K) | (646K) | (197K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (3.2M) | 0 | (350K) | 0 |
| Investing Cash Flow | (862K) | (4.11M) | (221K) | (646K) | (197K) |
| Debt Repayment | 0 | 0 | 10M | 18M | 360K |
| Common Stock Issued | 77.74M | 1.81M | 284K | 451K | 58.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.66M) | 804K | 551K | 451K | 0 |
| Financing Cash Flow | 72.08M | 2.61M | 29.46M | 48.25M | 59.03M |
| Effect of Forex Changes | (255) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 53.54M | (31.18M) | (3.58M) | 3.46M | 12.35M |
| Free Cash Flow | (18.53M) | (30.59M) | (33.04M) | (44.79M) | (46.49M) |
Lucid Diagnostics Inc.
NASDAQ:LUCD
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.